Appeal No. 2002-1358
Application No. 09/467,903
30. A pharmaceutical composition comprising a therapeutically effective amount
of a monoclonal antibody fragment bound to the surface of a liposome enclosing an
anti-cancer agent or toxin to cancer cells and a pharmaceutically acceptable carrier
therefor,
said liposome comprising phosphatidylcholine, cholesterol and
phosphatidylethanolamine,
said liposome being modified with poly(ethylene glycol), wherein the
poly(ethylene glycol) is bound to the surface of the liposome through a maleimide
group,
said antibody fragment belonging to IgG class or IgM class and specifically
binding to a surface antigen of a stomach and colon cancer cell membrane, and
said antibody fragment having a variable region of the heavy chain which
comprises the amino acid sequence shown in SEQ ID No: 5 and having a variable
region of the light chain which comprises the amino acid sequence of SEQ ID No:6.
34. The pharmaceutical composition of claim 30, wherein the monoclonal
antibody fragment is a F(ab')2 antibody fragment.
No prior art references are relied upon by the examiner.
The references relied upon by the appellants are:
Wright et al (Wright, “Antibody-directed liposomes as drug delivery vehicles,” Advanced
Drug Delivery Reviews, Vol. 3, pp. 343-389 (1989)
Singhal et al (Singhal), “Antibody-mediated targeting of liposomes to erythrocytes in
whole blood,” Biochimica et Biophysica Acta, Vol. 880, pp. 72-77 (1996)
Traut et al. (Traut), “Methyl 4- Mercaptobutyrimidate as a Cleavable Cross-Linking
Reagent and Its Application to the Escherichia coli 30S Ribosome,” Biochemistry, Vol.
12, No. 17 (1973)
Procedural Background
The original claims in the application were directed to a human monoclonal
antibody and an anti-cancer formulation comprising the antibody. Appellants filed a
preliminary amendment (Paper No. 2, Dec. 21, 1999), amending the claims to recite a
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007